Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Immunohorizons ; 1(4): 20-28, 2017 Jun 01.
Article in English | MEDLINE | ID: mdl-29202127

ABSTRACT

Sarcomas are a rare but fatal tumor type that accounts for <1% of adult solid malignancies and ~15% of childhood malignancies. Although the use of immunotherapy is being actively investigated for other solid tumors, advances in immunotherapy for sarcoma patients are lacking. To better understand the systemic immune environment in sarcoma patients, we performed a detailed multiplex analysis of serum cytokines, chemokines, and protumorigenic factors from treatment-naive subjects with localized, high-grade sarcoma. Because obesity is a major healthcare issue in the United States, we additionally examined the effects of obesity on serum protein profiles in our sarcoma subject cohort. We found that the systemic host environment is profoundly altered to favor tumor progression, with epidermal growth factor, angiopoietin-2, vascular endothelial growth factor A, IL-6, IL-8, and MIP-1ß all increased relative to tumor-free controls (all p < 0.05). Surprisingly, we found that obesity did not exacerbate this protumorigenic profile, as epidermal growth factor and IL-8 decreased with increasing subject body mass index (both p < 0.05 versus normal or overweight subjects). The Th2-related cytokines IL-4, IL-5, and IL-13 were also decreased in the presence of obesity. Thus, although the systemic environment in sarcoma subjects favors tumor progression, obesity does not further aggravate the production of protumorigenic factors.

2.
Urol Oncol ; 35(11): 661.e1-661.e6, 2017 11.
Article in English | MEDLINE | ID: mdl-28797586

ABSTRACT

OBJECTIVES: Obesity, typically defined as a body mass index (BMI)≥30kg/m2, is an established risk factor for renal cell carcinoma (RCC) but is paradoxically linked to less advanced disease at diagnosis and improved outcomes. However, BMI has inherent flaws, and alternate obesity-defining metrics that emphasize abdominal fat are available. We investigated 3 obesity-defining metrics, to better examine the associations of abdominal fat vs. generalized obesity with renal tumor stage, grade, or R.E.N.A.L. nephrometry score. METHODS AND MATERIALS: In a prospective cohort of 99 subjects with renal masses undergoing resection and no evidence of metastatic disease, obesity was assessed using 3 metrics: body mass index (BMI), radiographic waist circumference (WC), and retrorenal fat (RRF) pad distance. R.E.N.A.L. nephrometry scores were calculated based on preoperative CT or MRI. Univariate and multivariate analyses were performed to identify associations between obesity metrics and nephrometry score, tumor grade, and tumor stage. RESULTS: In the 99 subjects, surgery was partial nephrectomy in 51 and radical nephrectomy in 48. Pathology showed benign masses in 11 and RCC in 88 (of which 20 had stage T3 disease). WC was positively correlated with nephrometry score, even after controlling for age, sex, race, and diabetes status (P = 0.02), whereas BMI and RRF were not (P = 0.13, and P = 0.57, respectively). WC in stage T2/T3 subjects was higher than in subjects with benign masses (P = 0.03). In contrast, subjects with Fuhrman grade 1 and 2 tumors had higher BMI (P<0.01) and WC (P = 0.04) than subjects with grade 3 and 4 tumors. CONCLUSIONS: Our data suggest that obesity measured by WC, but not BMI or RRF, is associated with increased renal mass complexity. Tumor Fuhrman grade exhibited a different trend, with both high WC and BMI associated with lower-grade tumors. Our findings indicate that WC and BMI are not interchangeable obesity metrics. Further evaluation of RCC-specific outcomes using WC vs. BMI is warranted to better understand the complex relationship between general vs. abdominal obesity and RCC characteristics.


Subject(s)
Carcinoma, Renal Cell/pathology , Kidney Neoplasms/pathology , Kidney/pathology , Obesity/physiopathology , Waist Circumference/physiology , Aged , Body Mass Index , Female , Humans , Male , Middle Aged , Neoplasm Grading , Neoplasm Staging , Obesity/diagnosis , Obesity, Abdominal/physiopathology , Prospective Studies , Risk Factors
3.
Obesity (Silver Spring) ; 24(10): 2140-9, 2016 10.
Article in English | MEDLINE | ID: mdl-27515998

ABSTRACT

OBJECTIVE: Diet-induced obesity has been shown to alter immune function in mice, but distinguishing the effects of obesity from changes in diet composition is complicated. It was hypothesized that immunological differences would exist between diet-induced obese (DIO) and obese-resistant (OB-Res) mice fed the same high-fat diet (HFD). METHODS: BALB/c mice were fed either standard chow or HFD to generate lean or DIO and OB-Res mice, respectively. Resulting mice were analyzed for serum immunologic and metabolic profiles and cellular immune parameters. RESULTS: BALB/c mice on HFD were categorized as DIO or OB-Res, based on body weight versus lean controls. DIO mice were physiologically distinct from OB-Res mice, whose serum insulin, leptin, gastric inhibitory polypeptide, and eotaxin concentrations remained similar to lean controls. DIO mice had increased macrophage(+) crown-like structures in white adipose tissue, although macrophage percentages were unchanged from OB-Res and lean mice. DIO mice also had decreased splenic CD4(+) T cells, elevated serum GM-CSF, and increased splenic CD11c(+) dendritic cells, but impaired dendritic cell stimulatory capacity (P < 0.05 vs. lean controls). These parameters were unaltered in OB-Res mice versus lean controls. CONCLUSIONS: Diet-induced obesity results in alterations in immune and metabolic profiles that are distinct from effects caused by HFD alone.


Subject(s)
Diet, High-Fat , Obesity/metabolism , Animals , Body Weight/physiology , CD4-Positive T-Lymphocytes/metabolism , Chemokine CCL11/blood , Female , Insulin/blood , Leptin/blood , Male , Metabolome , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Obese , Obesity/immunology , Spleen/metabolism
4.
PLoS One ; 10(3): e0118784, 2015.
Article in English | MEDLINE | ID: mdl-25769110

ABSTRACT

Obesity is one of the leading risk factors for developing renal cell carcinoma, an immunogenic tumor that is treated clinically with immunostimulatory therapies. Currently, however, the mechanisms linking obesity with renal cancer incidence are unclear. Using a model of diet-induced obesity, we found that obese BALB/c mice with orthotopic renal tumors had increased total frequencies of myeloid-derived suppressor cells (MDSC) in renal tumors and spleens by d14 post-tumor challenge, relative to lean counterparts. Renal tumors from obese mice had elevated concentrations of the known myeloid cell chemoattractant CCL2, which was produced locally by increased percentages of dendritic cells, macrophages, B cells, and CD45- cells in tumors. MDSC expression of the CCL2 receptor, CCR2, was unaltered by obesity but greater percentages of CCR2+ MDSCs were present in renal tumors from obese mice. Of note, the intracellular arginase levels and per-cell suppressive capacities of tumor-infiltrating and splenic MDSCs were unchanged in obese mice relative to lean controls. Thus, our findings suggest that obesity promotes renal tumor progression via development of a robust immunosuppressive environment that is characterized by heightened local and systemic MDSC prevalence. Targeted intervention of the CCL2/CCR2 pathway may facilitate immune-mediated renal tumor clearance in the obese.


Subject(s)
Chemokine CCL2/biosynthesis , Kidney Neoplasms/immunology , Kidney Neoplasms/metabolism , Myeloid Cells/cytology , Myeloid Cells/immunology , Obesity/immunology , Animals , Cell Line, Tumor , Cell Proliferation , Chemokine CCL2/metabolism , Female , Gene Expression Regulation, Neoplastic/immunology , Immunotherapy , Kidney Neoplasms/complications , Kidney Neoplasms/therapy , Mice , Mice, Inbred BALB C , Obesity/complications , Species Specificity , Spleen/immunology
5.
Immunol Res ; 59(1-3): 12-22, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24847763

ABSTRACT

Numerous reports have described Toll-like receptor (TLR) functions in myeloid cells such as dendritic cells (DCs) and macrophages, but relatively fewer studies have examined TLR responses in B lymphocytes. B cells express a wide variety of TLRs and are highly activated after TLR ligation, leading to enhancements in B cell survival, surface molecule expression, cytokine and antibody production, and antigen presentation. During an immune response, B cells can receive signals through TLRs as well as the B cell antigen receptor (BCR) and/or CD40. TLR ligation synergizes with signals through these receptors and augments both innate and adaptive immune functions of B lymphocytes. Additionally, targeting B cell TLRs may provide new therapies against certain types of cancer as well as autoimmune diseases. Here, we summarize TLR expression and contributions to both normal and pathogenic functions in mouse and human B cells.


Subject(s)
Adaptive Immunity/physiology , Antibody Formation/physiology , B-Lymphocytes/immunology , Immunity, Innate/physiology , Receptors, Antigen, B-Cell/immunology , Toll-Like Receptors/immunology , Animals , Antigen Presentation/immunology , Antigen Presentation/physiology , B-Lymphocytes/cytology , CD40 Antigens/immunology , Dendritic Cells/cytology , Dendritic Cells/immunology , Humans , Macrophages/cytology , Macrophages/immunology , Mice , Portraits as Topic
6.
J Immunol ; 192(1): 145-50, 2014 Jan 01.
Article in English | MEDLINE | ID: mdl-24259503

ABSTRACT

The cytoplasmic adaptor proteins TNFR-associated factor (TRAF)3 and TRAF6 are important mediators of TLR signaling. To our knowledge, we show in this study for the first time that another TRAF family member, TRAF5, is a negative regulator of TLR signaling. B lymphocytes from TRAF5(-/-) mice produced more IL-6, IL-12p40, IL-10, TNF-α, and IgM than did wild-type B cells after TLR stimulation. Consistent with these data, exogenous overexpression of TRAF5 in B cells inhibited TLR-mediated cytokine and Ab production. TLR stimulation of TRAF5-deficient B cells did not affect cell survival, proliferation, or NF-κB activation but resulted in markedly enhanced phosphorylation of the MAPKs ERK1/2 and JNK. TRAF5 negatively regulated TLR signaling in a cell-specific manner, because TRAF5(-/-) macrophages and dendritic cells showed less dramatic differences in TLR-mediated cytokine production than B cells. Following TLR stimulation, TRAF5 associated in a complex with the TLR adaptor protein MyD88 and the B cell-specific positive regulator of TLR signaling TAB2. Furthermore, TRAF5 negatively regulated the association of TAB2 with its signaling partner TRAF6 after TLR ligation in B cells. To our knowledge, these data provide the first evidence that TRAF5 acts as a negative regulator of TLR signaling.


Subject(s)
B-Lymphocytes/metabolism , Signal Transduction , TNF Receptor-Associated Factor 5/genetics , TNF Receptor-Associated Factor 5/metabolism , Toll-Like Receptors/metabolism , Animals , Antibody Formation/immunology , B-Lymphocytes/immunology , Cell Line , Cytokines/biosynthesis , Dendritic Cells/metabolism , Macrophages/metabolism , Mice , Mice, Knockout , Myeloid Differentiation Factor 88 , Protein Binding
7.
PLoS One ; 8(6): e65599, 2013.
Article in English | MEDLINE | ID: mdl-23776508

ABSTRACT

Tumor metastasis plays a major role in the morbidity and mortality of cancer patients. Among solid tumors that undergo metastasis, there is often a predilection to metastasize to a particular organ with, for example, prostate cancer preferentially metastasizing to bones and colon cancer preferentially metastasizing to the liver. Although many factors are thought to be important in establishing permissiveness for metastasis, the reasons for organ-specific predilection of each tumor are not understood. Using a B16 murine melanoma model, we tested the hypothesis that organ-specific NK cell subsets play a critical role in organ-specific metastasis of this tumor. Melanoma cells, given intravenously, readily colonized the lungs but not the liver. NK cell depletion (either iatrogenically or by using genetically targeted mice) resulted in substantial hepatic metastasis. Analysis of NK cell subsets, defined by the differential expression of a combination of CD27 and CD11b, indicated a significant difference in the distribution of NK cell subsets in the lung and liver with the mature subset being dominant in the lung and the immature subset being dominant in the liver. Several experimental approaches, including adoptive transfer, clearly indicated that the immature hepatic NK cell subset, CD27+ CD11b-, was protective against liver metastasis; this subset mediated its protection by a perforin-dependent cytotoxic mechanism. In contrast, the more mature NK cell subsets were more efficient at reducing pulmonary tumor load. These data indicate that organ-specific immune responses may play a pivotal role in determining the permissiveness of a given organ for the establishment of a metastatic niche.


Subject(s)
Killer Cells, Natural/metabolism , Melanoma, Experimental/complications , Melanoma, Experimental/immunology , Animals , Cell Line, Tumor , Killer Cells, Natural/immunology , Liver Neoplasms/immunology , Liver Neoplasms/secondary , Lung Neoplasms/immunology , Lung Neoplasms/secondary , Male , Melanoma , Mice
8.
Immunol Rev ; 244(1): 55-74, 2011 Nov.
Article in English | MEDLINE | ID: mdl-22017431

ABSTRACT

A large and diverse group of receptors utilizes the family of cytoplasmic signaling proteins known as tumor necrosis factor receptor (TNFR)-associated factors (TRAFs). In recent years, there has been a resurgence of interest and exploration of the roles played by TRAF3 and TRAF5 in cellular regulation, particularly in cells of the immune system, the cell types of focus in this review. This work has revealed that TRAF3 and TRAF5 can play diverse roles for different receptors even in the same cell type, as well as distinct roles in different cell types. Evidence indicates that TRAF3 and TRAF5 play important roles beyond the TNFR-superfamily (SF) and viral mimics of its members, mediating certain innate immune receptor and cytokine receptor signals, and most recently, signals delivered by the T-cell receptor (TCR) signaling complex. Additionally, much research has demonstrated the importance of TRAF3-mediated cellular regulation via its cytoplasmic interactions with additional signaling proteins. In particular, we discuss below evidence for the participation by TRAF3 in a number of the regulatory post-translational modifications involving ubiquitin that are important in various signaling pathways.


Subject(s)
Immunity, Innate , NF-kappa B/immunology , Receptors, Tumor Necrosis Factor/immunology , Signal Transduction/immunology , TNF Receptor-Associated Factor 3/immunology , TNF Receptor-Associated Factor 5/immunology , Ubiquitin/immunology , Animals , B-Lymphocytes/immunology , B-Lymphocytes/metabolism , Cell Survival/genetics , Cell Survival/immunology , Gene Expression/immunology , Humans , Mice , Mice, Knockout , Myeloid Cells/immunology , Myeloid Cells/metabolism , NF-kappa B/genetics , NF-kappa B/metabolism , Protein Binding , Protein Processing, Post-Translational/genetics , Protein Processing, Post-Translational/immunology , Receptors, Tumor Necrosis Factor/genetics , Receptors, Tumor Necrosis Factor/metabolism , Signal Transduction/genetics , T-Lymphocytes/immunology , T-Lymphocytes/metabolism , TNF Receptor-Associated Factor 3/genetics , TNF Receptor-Associated Factor 3/metabolism , TNF Receptor-Associated Factor 5/genetics , TNF Receptor-Associated Factor 5/metabolism , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/immunology , Tumor Necrosis Factor-alpha/metabolism , Ubiquitin/genetics , Ubiquitin/metabolism
9.
J Immunol ; 183(8): 4833-7, 2009 Oct 15.
Article in English | MEDLINE | ID: mdl-19801508

ABSTRACT

B lymphocytes are a potential alternative to dendritic cell immunotherapy, with the advantages of relative abundance in peripheral blood and the ability to function as APCs. Although B cells express multiple receptors that induce costimulatory molecules, B cell vaccine studies have focused primarily on CD40 stimulation. To optimize the potential efficacy of B cell vaccines (Bvac), we compared the capacity of differentially stimulated B cells to induce Ag-specific CD8(+) T cell responses in vivo. CD40- or TLR7-stimulated B cell APCs induced similar CD8(+) T cell responses, but costimulation through the BCR and TLR7 produced a more effective Bvac as measured by T cell stimulation and the protection of mice from an infectious pathogen. This increased effectiveness depended upon enhanced production of IL-6 by BCR plus TLR7-stimulated B cells. These findings reveal alternative stimulation strategies for the production of effective Bvac and identify a key role for IL-6 in B cell Ag presentation and cellular vaccines.


Subject(s)
B-Lymphocytes/transplantation , CD8-Positive T-Lymphocytes/immunology , Interleukin-6/immunology , Vaccination , Vaccines/immunology , Animals , B-Lymphocytes/immunology , B-Lymphocytes/microbiology , CD8-Positive T-Lymphocytes/drug effects , CD8-Positive T-Lymphocytes/microbiology , Interleukin-6/metabolism , Interleukin-6/pharmacology , Listeria monocytogenes/immunology , Lymphocyte Activation/immunology , Membrane Glycoproteins/immunology , Mice , Mice, Inbred C57BL , Ovalbumin/immunology , Receptors, Antigen, B-Cell/immunology , Receptors, Antigen, B-Cell/metabolism , Toll-Like Receptor 7/immunology , Tumor Necrosis Factor-alpha/immunology , Tumor Necrosis Factor-alpha/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL